Table 2.
The weighted changes of clinical evaluations before and after treatment courses (n=19)a.
|
|
Precourse value | Postcourse value | Differenceb | P valuec | |||||||
|
|
Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) |
|
||||
| Self-rating score | |||||||||||
|
|
BASDAId scale | 3.7 (2.3) | 3.0 (2.4) | 2.7 (2.8) | 1.9 (4.5) | –1.0 (2.4) | –1.5 (1.6) | .08 | |||
|
|
BASFIe scale | 1.8 (2.2) | 0.8 (3.4) | 0.8 (1.3) | 0.6 (0.4) | –0.9 (1.7) | –0.2 (1.7) | .03c | |||
| Physical examination | |||||||||||
|
|
Schober test (cm) | 4.6 (3.8) | 5.0 (7.0) | 6.5 (3.5) | 6.0 (2.5) | 1.9 (4.9) | 2.0 (4.3) | .11 | |||
|
|
Finger-to-floor flexion test (cm) | 13.1 (14.2) | 10.0 (13.0) | 12.5 (9.0) | 11.0 (12.5) | –0.6 (9.5) | 0 (5.5) | .79 | |||
|
|
Enthesis score | 1.7 (2.3) | 1.0 (2.0) | 1.9 (3.1) | 0 (3.0) | 0.2 (2.6) | 0 (3.0) | .73 | |||
| Inflammatory factors and immunoglobulins | |||||||||||
|
|
IgGf | 1299.9 (294.4) | 1230.0 (300.0) | 1307.1 (324.4) | 1280.0 (480.0) | 7.2 (124.6) | 0 (130.0) | .8 | |||
|
|
IgA | 212.3 (69.6) | 227.0 (127.0) | 202.9 (57.9) | 221.0 (97.0) | –9.3 (31.1) | –3.0 (26.0) | .21 | |||
|
|
IgM | 91.0 (73.8) | 79.1 (74.0) | 94.6 (83.7) | 72.7 (87.3) | 3.7 (15.3) | 0.6 (18.1) | .31 | |||
|
|
ESRg | 16.4 (11.9) | 13.0 (13.0) | 14.7 (12.4) | 12.0 (23.0) | –1.7 (4.8) | –2.0 (6.0) | .15 | |||
|
|
CRPh | 5.1 (4.4) | 4.5 (6.4) | 4.3 (2.1) | 4.0 (4.4) | –1.3 (3.2) | –0.4 (4.5) | .09 | |||
| Cytokines and chemokines | |||||||||||
|
|
IL-1ßi (n=18) | 9.0 (14.3) | 5.9 (6.6) | 10.9 (15.4) | 4.7 (13.8) | 1.8 (10.5) | –0.3 (15.2) | .48 | |||
|
|
IL-3 (n=18) | 293.8 (843.6) | 7.8 (197.2) | 399.6 (1210) | 4.9 (208.0) | 105.9 (368.6) | –0.3 (3.3) | .25 | |||
|
|
IL-17F (n=18) | 3736.0 (11,741) | 197.4 (236.7) | 4035.3 (12,627) | 205.8 (394.4) | 299.2 (892.8) | 4.1 (110.0) | .18 | |||
|
|
IL-22 (n=18) | 16.8 (14.3) | 13.7 (8.0) | 16.5 (14.8) | 12.1 (9.4) | –0.3 (18.4) | 0.3 (6.0) | .95 | |||
|
|
IL-28 (n=18) | 105.3 (190.6) | 8.3 (182.8) | 109.0 (210.3) | 3.1 (171.8) | 3.7 (24.7) | 0 (5.2) | .54 | |||
|
|
IL-34 (n=18) | 49.1 (125.9) | 3.9 (20.8) | 62.8 (178.0) | 2.0 (27.3) | 13.7 (53.4) | –2.0 (2.6) | .30 | |||
|
|
CCL-2 (MCP-1j; n=18) | 169.3 (294.5) | 95.6 (67.9) | 195.1 (444.6) | 57.9 (123.1) | 25.8 (154.7) | 0.7 (57.1) | .49 | |||
|
|
CCL-22 (MDCk; n=18) | 625.3 (296.8) | 587.2 (318.4) | 600.0 (286.7) | 583.8 (403.4) | –25.3 (242.7) | –78.5 (142.6) | .67 | |||
aThe 1-month course was used as the weighting basis, and the 2-month course weighed 2. In sum, this study included nine 1-month courses and five 2-month courses, resulting in 19 weighted courses.
bDifference was calculated by the postcourse value minus the precourse value in pairs.
cP value was calculated by paired 2-tailed t test for weighted paired results; P<.05.
dBASDAI: Bath Ankylosing Spondylitis Disease Activity Index.
eBASFI: Bath Ankylosing Spondylitis Functional Index.
fIg: immunoglobin.
gESR: erythrocyte sedimentation rate.
hCRP: C-reactive protein.
iIL: interleukin.
jMCP-1: monocyte chemoattractant protein 1.
kMDC: monodansylcadaverine.